title: MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
abstract: BACKGROUND
  We aimed to investigate the function of miR-1307 in chemoresistance and to explore its chemoresistance mechanism in ovarian cancer.
  
  
  METHODS
  IC50 determination was used to test the chemoresistance profling in ovarian cancer cells. QRT-PCR or western blot was used to validate the expression level of miR-1307 and candidate gene or protein. Colony formation assay and FITC-labeled enhanced Annexin V immunofluorescence were used to compare cell proliferation and apoptosis ability, respectively. The potential target gene and its biological function of miRNA-1307 were also analyzed. Bioinformatics and Luciferase Reporter Gene Assay were conducted to validate the regulation of miRNA-1307 on the ING5 expression. Xenografts assay was used to demonstrate the inhibiting effect of miR-1307 ASO and Taxol therapy against ovarian cancer in vivo.
  
  
  RESULTS
  MiR-1307 was over-expressed in chemoresistant ovarian cancer cell line A2780/Taxol, and over-expression or loss of miR-1307 promoted or inhabited chemoresistance. And we also found that the over-expression of miR-1307 promoted proliferation and inhibited apoptosis in ovarian cancer cells. Besides, we demonstrated that ING5 was a direct target of miR-1307 and miR-1307 down-regulated the ING5 expression in ovarian cancer cells. Additionally, we showed that ING5 inhibited cell proliferation, promoted cell apoptosis and inhabited chemoresistance reversely. Furthermore, the up-regulated ability of cell apoptosis and down-regulated ability of chemoresistance following the loss of miR-1307 was reversed by adding ING5 siRNA in vitro. Finally, we proved the inhibiting effect of miR-1307 ASO and Taxol therapy by increasing the ING5 expression against ovarian cancer through xenografts assay in vivo.
  
  
  CONCLUSIONS
  Our results suggested that miR-1307 could promote ovarian cancer chemoresistance by targeting the ING5 expression and miR-1307 might serve as a therapeutic target for ovarian cancer.
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Wen-Ting
authors.initials: WT
authors.lastname: Chen
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Yu-Jia
authors.initials: YJ
authors.lastname: Yang
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Zhen-Dong
authors.initials: ZD
authors.lastname: Zhang
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: An
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Na
authors.initials: N
authors.lastname: Li
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.affiliation: Affiliated hospital of Zunyi Medical College, Zunyi, Guizhou, 563000, People's Republic of China. bingyang810@163.com.
authors.forename: Bing
authors.initials: B
authors.lastname: Yang
mesh_terms: D020413:3' Untranslated Regions; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000235:genetics; D001665:Binding Sites; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival / Q000235:genetics; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology; D034622:RNA Interference; D014157:Transcription Factors / Q000235:genetics*; D014162:Transfection; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020413:3' Untranslated Regions; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; C508131:ING5 protein, human; C000610094:MIRN1307 microRNA, human; D035683:MicroRNAs; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D017239:Paclitaxel
keywords: Cell chemoresistance; ING5; Ovarian cancer; miR-1307